Showing results (21-30 of 35) with videos related to
Sort By:
Pageof 4
European Thyroid Journal|June 20, 2025
Molecular predictive biomarker testing in advanced thyroid cancer - a European consensusAleš Ryška, Jaume Capdevila, Matthias S Dettmer, et al.Investigational New Drugs|May 16, 2020
A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatmentJean-Pierre Delord, Guillem Argilés, Jerôme Fayette, et al.The Lancet. Diabetes & Endocrinology|May 3, 2025
Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statementSophie Leboulleux, Laura Boucai, Naifa Busaidy, et al.Oral Oncology|March 3, 2018
Oncologic and functional outcomes of pretreatment tracheotomy in advanced laryngeal squamous cell carcinoma: A multi-institutional analysisSerena A Byrd, Mary J Xu, Lauren M Cass, et al.Frontiers in Oncology|November 16, 2016
Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)Jérôme Fayette, Lori Wirth, Cristina Oprean, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2017
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II StudyJoshua Bauml, Tanguy Y Seiwert, David G Pfister, et al.Head & Neck|December 3, 2020
Limitations of preoperative cytology for medullary thyroid cancer: Proposal for improved preoperative diagnosis for optimal initial medullary thyroid carcinoma specific surgeryAlan D Workman, Selen Soylu, Dipti Kamani, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2026
Systemic Treatment of Thyroid Cancer: ASCO GuidelineNabil F Saba, Nofisat Ismaila, Douglas Adkins, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 15, 2014
Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancerNeil D Gross, Julie E Bauman, William E Gooding, et al.Medrxiv : the Preprint Server for Health Sciences|December 8, 2025
Clinical validation of an HPV whole genome sequencing assay for molecular residual disease detection in HPV-associated head and neck cancer patients treated with surgeryShun Hirayama, Yana Al-Inaya, Michael E Bryan, et al.Pageof 4